| H01457 | |
| H number | H01457 |
| Name | Diabetic retinopathy |
| Description | Diabetic retinopathy (DR), one of the most common vascular complication of diabetes, is the leading cause of visual deficits and blindness around the world. The development of DR is divided into two stages: in the early stages, also called as nonproliferative stage, it is asymptomatic because the signs are not visible to the eye. however, some defects including microaneurysms, intraretinal hemorrhaging, narrowing or blocked retinal blood vessels can be seen by detection; in the second stage, known as proliferative diabetic retinopathy, where neovascularization appears at the back of the eye and extend into the vitreous of the eye, and these new blood vessels are fragile. If they leak blood, the bleeding causes shrinkage of the retina, leading to retinal detachment, and ultimately to blindness. It has been reported that vascular endothelial growth factor A, angiotensin-converting enzyme, paraoxonase, erythropoietin are associated with DR development and progression. |
| Category | Endocrine and metabolic disease; Nervous system disease |
| Network | - |
| Gene | VEGFA [HSA:7422] [KO:K05448] EPO [HSA:2056] [KO:K05437] ACE [HSA:1636] [KO:K01283] PON1 [HSA:5444] [KO:K01045] |
| Pathogen | - |
| Env factor | - |
| Carcinogen | - |
| Drug | Aflibercept [DR:D09574] Ranibizumab [DR:D05697] |
| Comment | - |
| Other DBs | ICD-11: 9B71.0 ICD-10: E14.3 MeSH: D003930 OMIM: 603933 612623 612624 612633 |
| Reference | PMID:26648684 AUTHORS Hampton BM, Schwartz SG, Brantley MA Jr, Flynn HW Jr TITLE Update on genetics and diabetic retinopathy. JOURNAL Clin Ophthalmol 9:2175-93 (2015) DOI:10.2147/OPTH.S94508 PMID:25949073 AUTHORS Dedania VS, Bakri SJ TITLE Novel pharmacotherapies in diabetic retinopathy. JOURNAL Middle East Afr J Ophthalmol 22:164-73 (2015) DOI:10.4103/0974-9233.154389 PMID:11978667 (VEGFA) AUTHORS Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S TITLE A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. JOURNAL Diabetes 51:1635-9 (2002) DOI:10.2337/diabetes.51.5.1635 PMID:18458324 (EPO) AUTHORS Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon J, Pearson E, Buehler J, Chen Y, Yu B, Tinkham NH, Zabriskie NA, Zeng J, Luo L, Sun JK, Prakash M, Hamam RN, Tonna S, Constantine R, Ronquillo CC, Sadda S, Avery RL, Brand JM, London N, Anduze AL, King GL, Bernstein PS, Watkins S, Jorde LB, Li DY, Aiello LP, Pollak MR, Zhang K TITLE Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. JOURNAL Proc Natl Acad Sci U S A 105:6998-7003 (2008) DOI:10.1073/pnas.0800454105 PMID:9120002 (ACE) AUTHORS Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F TITLE Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. JOURNAL J Clin Invest 99:1585-95 (1997) DOI:10.1172/JCI119321 PMID:9661650 (PON1) AUTHORS Kao YL, Donaghue K, Chan A, Knight J, Silink M TITLE A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. JOURNAL J Clin Endocrinol Metab 83:2589-92 (1998) DOI:10.1210/jcem.83.7.5096 |